Glaukos Corp (NASDAQ:GKOS) saw notable insider activity on April 30, 2026, when Senior Vice President and Chief Financial Officer Alex R. Thurman sold 10,000 shares of common stock. The total value of this sale reached $1,400,000, with the shares being moved at a price of $140.00 per share. This specific pricing level is relatively close to the stock's recent 52-week high of $146.75. While the company has seen a 55% return over the past year, current analysis from InvestingPro indicates that Glaukos may be trading at a valuation higher than its calculated Fair Value.
The sale was part of a dual-step transaction process facilitated by a Rule 10b5-1 trading plan adopted by Mr. Thurman on December 15, 2025. Earlier in the same day, Mr. Thurman exercised options to purchase 10,000 shares of Glaukos common stock at an exercise price of $38.68 per share, which amounted to a total cost of $386,800. These option exercises are subject to a four-year vesting schedule from the date of the grant; specifically, 25% of the options vest on the first anniversary, with the remaining portion vesting in equal monthly installments over the subsequent three years.
Following these recent moves, Mr. Thurman's direct holdings in Glaukos common stock stand at 43,681 shares. This figure encompasses 5,230 restricted stock units that are currently unvested and have not yet been delivered. Furthermore, he maintains a position of 30,000 unexercised stock options.
These insider transactions take place against the backdrop of Glaukos' recent financial reporting for the first quarter of 2026. The company reported earnings per share (EPS) of -$0.18, a figure that outperformed the anticipated analyst forecast of -$0.28. On the revenue front, Glaukos posted $150.6 million, which surpassed the expected $137.04 million and represented a 41% increase compared to the previous year. Following these strong results, the company issued an upward revision for its full-year 2026 revenue guidance.
Market analysts have provided updated outlooks following the quarterly report. Needham raised its price target for Glaukos to $136, noting that the revenue beat was supported by the performance of the company's glaucoma business. Similarly, BTIG increased its price target to $141, pointing toward robust first-quarter results that exceeded both consensus and their own internal estimates. However, despite the positive financial data, investor sentiment showed signs of being mixed, as evidenced by a slight decrease in the stock price during after-hours trading.